ShernanGHoltanMD- Allogeneic HCT/ Cell Therapy(She/Her)

PubMed

• JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
  Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
  Blood. 2024-11-28
• Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Singl...
  Marketa Dimitrov, Svatava Merkle, Qing Cao, Rebecca K Tryon, Gregory M Vercellotti
  Transplantation and Cellular Therapy. 2024-10-01
• Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors.
  Najla El Jurdi, Hok Sreng Te, Qing Cao, Char Napurski, Shuo Wang
  Aging. 2024-09-26

Journal Articles

• Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid  
  Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
• Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors  
  Jeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
• Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma  
  Enninga EAL, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN, Mayo Clinic Proceedings, 1/1/2014
• Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning  
  DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, Patnaik M, Litzow M, Hogan W, Porrata L, Holtan SG, Bone Marrow Transplant, 1/1/2013
• Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant  
  Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, Hogan WJ, Porrata LF, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2012
• Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial  
  Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP, PloS one, 1/1/2012
•  
  Holtan SG, O'Connor HM, Fredericksen ZS, Liebow M, Thompson CA, Macon WR, Micallef IN, Wang AH, Slager SL, Habermann TM, International Journal of Cancer, 1/1/2012
• Graft vs GIST?  
  Holtan SG, Palmer S, Okuno S, Hogan W, Bone Marrow Transplant, 1/1/2012
• Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis  
  Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN, Modern Pathology, 1/1/2011
• Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma  
  Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN, Clinical and Developmental Immunology, 1/1/2011
• An organ system based approach to prognosis in advanced melanoma  
  Holtan SG, Mansfield A, Creedon D, Nevala W, Haluska P, Leontovich A, Markovic S, Frontiers in bioscience (Elite edition), 1/1/2011
• Mother knows best: lessons from fetomaternal tolerance applied to cancer immunity  
  Holtan SG, Creedon D, Frontiers in bioscience (Scholar edition), 1/1/2011
• WHO-defined ‘myelodysplastic syndrome with isolated del (5q)’in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and I...  
  Patnaik M, Lasho T, Finke C, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson R, Ketterling R, Chen D, Leukemia, 1/1/2010
• Constrictive Pericarditis Due to Graft-vs-Host Disease  
  Holtan SG, Spittell PC, Mayo Clinic Proceedings, 1/1/2010
• Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count  
  Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP, American journal of hematology, 1/1/2010
• Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents  
  Holtan SG, Creedon DJ, Haluska P, Markovic SN, Mayo Clinic Proceedings, 1/1/2009
• Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del (5q): clinicopathologic comparison of del (5q)-positive and-negative cases  
  Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA, Leuk Res, 1/1/2008
• Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era  
  American journal of hematology, 1/1/2008
•  
  Holtan SG, Porrata LF, Colgan JP, Zent CS, Habermann TM, Markovic SN, American journal of hematology, 1/1/2008
• AMD3100 Affects Autograft Lymphocyte Collection and Progression-Free Survival After Autologous Stem Cell Transplantion in Non-Hodgkin Lymphoma  
  Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2007
• Knowing too much  
  Holtan SG, Journal of Cancer Education, 1/1/2007
• Diagnosis of obesity by primary care physicians and impact on obesity management  
  Bardia A, Holtan SG, Slezak JM, Thompson WG, Mayo Clinic Proceedings, 1/1/2007
•  
  Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN, Cancer, 1/1/2006
•  
  Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Litzow MR, Gastineau DA, Markovic SN, Br J Haematol, 1/1/2006
•  
  Holtan SG, Knox S, Tefferi A, Journal of Thrombosis and Haemostasis, 1/1/2006
• Join now to see all

Abstracts/Posters

• Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
  Shernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
• Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
  Shernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Impact of Follistatin in Acute Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802
  Holtan, SG., Michael R. Verneris, Kirk R Schultz, Laura F. Newell, Gabrielle Meyers, Fiona He, Todd E. DeFor, Margaret L. MacMillan, Biology of Blood and Marrow Transplant, 1/1/2015
• Chronic Graft-versus-Host Disease Biomarker Discovery andReplication: CXCL10 + CXCL9 Provides the Highest Diagnostic Value in Adults
  Amina Kariminia, Holtan, SG., Marie-Josee Hebert, Paul Martin, Stephanie J. Lee, Jan Storek, Stephen Couban, David Szwajcer, Laura Newell, Irwin Walker, Jason Tay, Jo..., CBMTG, 1/1/2015
• Chronic Graft-versus-Host Disease Biomarker Discovery and Replication
  Kirk R. Schultz, Amina Kariminia , Sabine Ivison, Holtan, SG., Marie-Josee Hebert , Mary E.D. Flowers, Paul Martin, Jacob Rozmus, Peter Subrt, Barry Storer, Stephanie ..., EBMT, 1/1/2015
• Allograft Leukocyte Content and Post-Allogeneic Hematopoietic Cell Transplant Lymphopenia and Monocytopenia
  Thoma M, Glejf J, Jacob EK, Huneke T, DeCook L, Johnson N, Patnaik M, Litzow M, Hogan W, Porrata L, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2013
• Chronic GVHD-Associated Serositis and Pericarditis
  Leonard J, Holtan SG, Heitner S, Nonas S, Allen B, Chen AI, Newell LF, Meyers G, Hayes-Lattin B, Gajewski J, Biology of Blood and Marrow Transplantation, 1/1/2013
• Predictive Classification of Chronic GVHD Status by Immune Reconstitution Testing
  Holtan SG, Newell LF, Meyers G, Chen AI, Hayes-Lattin B, Gajewski J, Slater S, Nemecek E, Braziel R, Fan G, Biology of Blood and Marrow Transplantation, 1/1/2013
• Factor Analysis of the Longitudinal Maternal Immune Response to Pregnancy
  Holtan SG, Creedon D, Nevala W, Leontovich A, Markovic S, Journal of Womens Health, 1/1/2013
• Redefining Engraftment Syndrome: The New Mayo Clinic Criteria
  Burnette BL, Holtan SG, Gertz M, Kumar S, Lacy M, Buadi F, Hayman S, Dingli D, Inwards DJ, Johnston PB, Micallef IN, Dispenzieri A, Biology of Blood and Marrow Transplantation, 1/1/2013
• Exhibition of a stem-cell like phenotype with the expression of CD271 in drug-resistant melanoma cells
  Lieser EAT, Leontovich AA, Holtan SG, Nevala WK, Markovic S, Journal of Clinical Oncology, Amer Soc Clinical Oncology, 1/1/2012
• G-CSF Mobilization Alone, a Shorter Duration of Neutropenia, and the Rapidity of Engraftment Are Associated with Engraftment Syndrome in Patients Undergoing Autologous...
  Burnette B, Dispenzieri A, Porrata L, Hogan W, Holtan SG, Biology of Blood and Marrow Transplantation, 1/1/2012
• Impact of Rapid Lymphocyte and Monocyte Recovery on Overall Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine/Melphalan Conditio...
  DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, Litzow MR, Hogan WJ, Porrata LF, Holtan SG, Blood, Amer Soc Hematology, 1/1/2011
• Maternal Systemic Immune Networks During Mid-Gestation
  Creedon D, Nevala W, Leontovich A, Markovic S, Holtan SG, Placenta, 1/1/2011
• Pneumocystis pneumonia in patients with lymphoma: Who should receive prophylaxis?
  Solomon B, Holtan SG, Letendre L, J Clin Oncol, 1/1/2010
• Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation
  Holtan SG, Creedon D, Leontovich A, Markovic S, J Clin Oncol, 1/1/2010
• Using Fetomaternal Interactions To Identify Immunomodulatory Mechanisms In Melanoma
  Holtan SG, Mansfield A, Creedon D, Nevala W, Leontovich A, Markovic S, Placenta, 1/1/2010
• CD34+ Cell Dose and Full Donor Chimerism at Day+ 100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphal...
  Holtan SG, Hogan W, Elliott M, Gastineau D, Call T, Ansell S, Inwards D, Johnston P, Lacy M, Micallef I, Biology of Blood and Marrow Transplantation, 1/1/2009
• Food-Frequency Questionnaire (FFQ) Based Estimates of Total Antioxidant Capacity and Risk of Non-Hodgkin Lymphoma (NHL)
  Cerhan J, Holtan SG, O'Connor H, Fredericksen Z, Liebow M, Macon W, Wang A, Slager S, Habermann T, Call T, Cancer Ipidemiology Biomakers & Prevention, Amer Assoc Cancer Research, 1/1/2009
• Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution
  Santana-Davila R, Holtan SG, Ketterling R, Knudson RA, Steensma DP, Chen D, Hoyer J, Hanson CA, Tefferi A, Blood, Amer Soc Hematology, 1/1/2008
• Low Absolute Lymphocyte Count (ALC) at Diagnosis Is An IPSS-Independent Predictor of Poorer Survival in Myelodysplastic Syndromes (MDS)
  Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP, Blood, Amer Soc Hematology, 1/1/2008
• Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study
  Holtan SG, Call TG, Fredericksen ZS, O'Connor HM, Liebow M, Macon WR, Kay NE, Micallef IN, Wang AH, Slager SL, Blood, Amer Soc Hematology, 1/1/2008
• Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial
  Holtan SG, Foster N, Erlichman C, Aubry M, Ames M, Safgren S, Steen P, Morton R, Graham D, Goetz M, J Clin Oncol, 1/1/2008
• Deletion 5q in WHO-Defined Myeloproliferative Neoplasms: A Clinicopathological Description
  Santana-Davila R, Tefferi A, Holtan SG, Ketterling R, Knudson R, Steensma D, Chen D, Hoyer J, Hanson C, Blood, 1/1/2007
• Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma
  Holtan SG, Porrata LF, Inwards DJ, Ansell SA, Padley DJ, Micallef IN, Litzow MR, Johnston PB, Hayman SR, Kumar SK, Blood, 1/1/2005
• Join now to see all

Lectures

• Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes! 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Prognostic Impact of Follistatin in Acute Graft Versus Host Disease: Results from BMT CTN 0302 and 0802 
  San Diego, CA - 1/1/2015
• What predicts Success for a New Composite Endpoint: Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) After Allogeneic Hematopoietic Cell Transplantation? 
  San Francisco, CA - 1/1/2014
• Chemotherapy 101 and Chemotherapy Emergencies 
  1/1/2009
• Taxol/carboplatin as salvage therapy for stage IV melanoma 
  Rochester, MN - 1/1/2005
• How Happy and Healthy are Physicians and Medical Students 
  Los Angeles, CA - 1/1/2001
• Fetomaternal tolerance: Implications for novel immune-based cancer therapeutics 
  1/14/2009
• Pregnancy and Cancer: Intriguing Parallels 
  Rochester, MN - 1/22/2009
• Pregnancy and Cancer 
  1/22/2010
• Inflammation and tolerance: Similarities in pregnancy and melanoma 
  1/24/2009
• Management of Allogeneic Transplant Patients 
  Portland, OR - 1/12/2013
• Coping with the Late and Long Term Side Effects of Stem Cell Transplants 
  Portland, OR - 1/20/2013
• BMT: Supportive Care and Early Complications 
  University of Minnesota - 1/19/2014
• Join now to see all

Other

• Cancer of Unknown Primary Site 
  Holtan SG, Enterprise Learning System, AskMayoExpert article, Mayo Clinic
  1/1/2009